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Chronic kidney disease and cardiovascular disease in the Medi-
care population.
Background. The extent of diabetes, chronic kidney disease
(CKD), and cardiovascular disease (CVD) in the Medicare
population is relatively unknown. Also unknown is the effect
of these diseases on patient survival before end-stage renal
disease (ESRD).
Methods. Prevalent cohorts of Medicare enrollees from 1996
to 2000 were assessed for diabetes and CKD, presence of CVD,
and probability of death versus ESRD in the follow-up period.
Hospitalization rates and, in diabetics, lipid testing and gly-
cemic control monitoring were also assessed.
Results. The prevalence of diabetes in the Medicare popula-
tion increased at 4.4% per year, reaching 18.9% in the 1999–
2000 cohort. Approximately 726,000 elderly Medicare enrollees
carry a diagnosis code for CKD. Those with CKD are 5 to 10
times more likely to die before reaching ESRD than the non-
CKD group. In CKD patients, CVD is twice as common and
advances at twice the rate. Cardiovascular disease advances at
a similarly higher rate in CKD patients who die and those who
survive to ESRD. Heart failure hospitalizations are 5 times
greater in CKD patients and only 30% less than those in dialysis
patients. Only half of the CKD patients with diabetes who
advance to ESRD had a lipid or glycosylated hemoglobin test
done in the year before or after dialysis initiation.
Conclusion. Diabetes, the leading cause of ESRD, is increas-
ing in the general Medicare population at 4.4% per year. Car-
diovascular disease is common, progresses at twice the rate,
is associated with death before ESRD, and patients receive
suboptimal risk factor monitoring. Active identification and
treatment of CKD patients is needed.
Public health officials in the United States have ex-
pressed concern about the increasing number of patients
reaching end-stage renal disease (ESRD) [1]. On the
basis of previously reported trends, the number of pa-
tients receiving dialysis may exceed 560,000 by the year
2010 [2, 3]. The potential long-term growth of the United
States ESRD program (and associated high death rates)
has prompted the Department of Health and Human
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Services to establish objectives related to kidney disease
[1]. These objectives include reductions in the incident
rate of ESRD, the extent of ESRD due to diabetes melli-
tus, and cardiovascular death rates in patients with kid-
ney disease.
The dramatic 40-fold higher death rates among dialysis
patients, as compared to the general population that was
first reported by Sarnak and Levey [4] appears to be
associated with the heavy burden of cardiovascular dis-
ease (CVD) among patients with ESRD. Improvements
in the quality of the delivered dialysis and anemia correc-
tion have been associated with improved survival in the
1990s [5, 6]. Nevertheless, the prevalence of CVD at
initiation of dialysis increased dramatically from 25% in
1984 to 40% by 1999, as shown in the United States
Renal Data System (USRDS) 2002 Annual Data Report
[5]. The high rates of CVD are associated with cardiovas-
cular death, which contributes to the 20% to 23% annual
prevalent mortality of the dialysis population, as shown
in the USRDS 2002 Annual Data Report [5].
Because CVD occurs at a higher rate in patients with
elevated serum creatinine levels [7–9], it has been sug-
gested that earlier identification and treatment of CVD
in patients with chronic kidney disease (CKD) may re-
duce the severity of disease, thereby improving the out-
comes of those who reach ESRD treatment. The size
of the CKD population has been unknown. Recently,
however, it has become apparent that the public heath
problem associated with CKD is greater than previously
appreciated. Using methods developed by Coresh et al
[10], the National Kidney Foundation estimated that ap-
proximately 8 million individuals have an estimated glo-
merular filtration rate (eGFR) of 60 mL/min [11], and
that 5.9 million of these individuals appear to be in the
Medicare system within the group of enrollees aged 65
years and older [5]. The outcomes of these CKD patients
before they reach ESRD have been unknown. Given
that only 100,000 patients start dialysis each year [5], it is
unclear what happens to most of the 8 million individuals
with mild to advanced CKD (eGFR 60 mL/min).
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We studied the Medicare population to determine the
extent of clinically recognized CKD, the prevalence of
associated CVD, and advancement toward ESRD or
death.
METHODS
The study population consisted of general Medicare
enrollees from 1996 through 2000 who were in the fee-
for-service system. These individuals were identified
from the 5% random sample of Medicare enrollees
whose data are available to clinical researchers [12]. For
each year assessed, the study population consisted of
approximately 1.1 million individuals. Two-year entry
period cohorts were created to allow characterization
of their medical conditions, as previously described by
Hebert et al [13]. Each cohort included patients who had
both Part A and Part B Medicare coverage simultane-
ously, were alive and aged 67 years or older on the last
day of the entry period, did not have ESRD, and resided
in the 50 states, the District of Columbia, Puerto Rico,
or the territories. To allow tracking of medical conditions
and diagnosis codes, we excluded individuals who were
in the health maintenance organization option (i.e.,
MedicareChoice) and had Medicare as a secondary
payer. Diabetes was defined by a well-established method
[14] using Medicare claims documenting diabetes for
the years 1996 through 2000. The current prevalence of
diabetes in the Medicare population was compared to
the first published prevalence (i.e., prevalence reported
for the years 1992 through 1993) [13]. The comparative
growth in the prevalence of diabetes in the general popu-
lation was determined with use of results obtained by
the Centers for Disease Control and Prevention (CDC)
in a study of the prevalence of obesity and diabetes
among United States adults in the year 2000 [15].
Patients with CKD were identified from International
Classification of Diseases, Ninth Revision, Clinical Mod-
ification (ICD-9-CM) diagnosis codes in a manner similar
to the method used by other investigators to identify
patients with diabetes and other chronic diseases [13, 14].
Coded conditions for which data were gathered included
CKD from diabetes, hypertension, obstructive uropathy,
and other diagnosis codes, as reported to the USRDS
on the ESRD registration form [i.e., Medical Evidence
Report, Centers for Medicare & Medicaid Services
(CMS) Form 2728] [5]. Patients with CVD were identi-
fied using ICD-9-CM codes in a manner similar to that
used to identify patients with CKD, with specific atten-
tion paid to those with congestive heart failure, ischemic
heart disease, cerebral vascular accidents and transient
ischemic attacks, peripheral vascular disease, and other
arrhythmic disorders.
The trends in prevalence of diabetes from 1996 to 2000
were estimated using the two-year entry period cohorts.
Analyses of the progression to ESRD, the risk of death
versus ESRD, and the burden of cardiovascular disease
in general Medicare patients were performed in the 1996
to 1997 patient cohort using 3 epidemiologic models.
In the first model, the development of ESRD and its
relationship to certain comorbid conditions were evalu-
ated. All Medicare patients who did not have a diagnosis
of ESRD from 1996 to 1997 were followed for 1 year
starting on January 1, 1998. Patients were categorized
as having diabetes, CKD, both diabetes and CKD, or
neither diabetes nor CKD. The proportion of non-ESRD
patients represented by each disease group was calcu-
lated. Then, with the focus on patients who developed
ESRD during the follow-up period, the proportion rep-
resented by each disease group was computed.
In the second model, the risk of death versus ESRD
among the 4 disease groups was compared. All patients
were followed for 2 years starting on January 1, 1998,
to monitor the outcome of ESRD or death. The percent-
age of patients who died, developed ESRD, or were
alive without either event was determined. For patients
of each disease group, the probability of death versus
ESRD was estimated by determining the ratio of the
percentage of patients who died to the percentage of
patients who developed ESRD.
In the third model, the prevalence and incidence of
CVD were assessed. The same 2-year entry period was
used (1996 to 1997); however, patients also were required
to survive an additional year (1998) to allow determina-
tion of the rate of CVD diagnosis codes reported in
claims for services. Patients who developed ESRD or
were newly identified as having CKD in 1998 were ex-
cluded because this was an outcome variable in the
fourth year (1999). In 1999, the outcome of death, ESRD,
or being alive on December 31, 1999, without either
event was determined for the CKD patients identified
in the 1996 to 1997 entry period, and the outcome of
death, ESRD, CKD, or being alive on December 31,
1999, without any of these events was determined for
the non-CKD patients identified in the entry period.
Prevalence and incidence of CVD were estimated in
the 1996 to 1997 entry period and the 1998 follow-up
period, respectively. Life table estimation method was
used to determine the cumulative probability of incident
cardiovascular disease in 1998 by examining CKD status
in 1996 and 1997 and outcomes in 1999. A Cox propor-
tional hazards model was used to estimate the relative
risk for incident CVD between CKD and non-CKD pa-
tients, with age, gender, and race used as covariates.
Hospitalization and overall mortality rates were deter-
mined for individuals who did not have a diagnosis of
CKD, for those who did have a diagnosis of CKD, and
for the dialysis population. Patients also were grouped
into diabetics and nondiabetics. Cause-specific hospital-
izations were categorized as cardiovascular disease, in-
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Fig. 1. Percentage of respondents reporting a diagnosis of diabetes
in the Behavioral Risk Factor Surveillance System survey, 1990–2000
[14–16].
fection, or other causes. Cardiovascular hospitalizations
were further categorized according to principal diagno-
sis: congestive heart failure, ischemic heart disease, or
other CVD.
Preventive health care measures used in the general
population before and after initiation of dialysis also
were investigated in this Medicare population. Data on
patients aged 67 years and older who received dialysis
were reviewed for the year before and the year after
ESRD treatment was begun, as described in the USRDS
2002 Annual Data Report [5]. The percentage of patients
receiving care for diabetes (including lipid testing and
glycosylated hemoglobin testing) was assessed in the
1-year period before and after initiation of ESRD treat-
ment.
RESULTS
Figure 1 shows the percentage of individuals in the
general population reporting a diagnosis of diabetes in
telephone surveys conducted by the CDC [14–16]. Dur-
ing the 1990 to 2000 period, the self-reported prevalence
of diabetes in the general population increased from
4.9% to 7.4%, a 51% increase, or an average annual rate
increase of 4.2% per year.
Figure 2 shows the prevalence of diabetes in the Medi-
care population in 1992 to 1993 versus 1996 to 2000. In
1992 to 1993, 13.6% of the Medicare population had a
diagnosis of diabetes [13]. By 1999 to 2000, this preva-
lence had reached 18.9%, for an average annual increase
over the 7-year period of 4.4%. The percentage of elderly
individuals with diabetes in the Medicare population was
comparable to that found by the CDC [15].
Figure 3 reports on elderly Medicare patients in the
1996 to 1997 entry period who were followed for 1 year
for development of ESRD. The figure shows that, of
the 1.1 million individuals in the 5% Medicare sample
(representing approximately 22.7 million Medicare fee-
Fig. 2. Prevalence of diabetes in the Medicare population, 1992–1993
[13] versus 1996-2000.
Fig. 3. Prevalence of diabetes mellitus (DM) and chronic kidney dis-
ease (CKD) in the Medicare population, 1996–1997, and progression
to end-stage renal disease (ESRD) during 1-year follow-up.
for-service enrollees in the full sample), 1.3% had a diag-
nosis of diabetes and CKD; this represented approxi-
mately 288,000 enrollees in the full Medicare sample.
Approximately 15.2% had a diagnosis of diabetes with-
out CKD; this represented approximately 3.5 million
enrollees. Among nondiabetics, those with a diagnosis
of CKD accounted for 1.9% of the 5% Medicare sample,
representing approximately 438,000 enrollees in the full
Medicare sample; those without a diagnosis of CKD
accounted for 81.6% of the sample, representing approx-
imately 18.5 million enrollees in the full Medicare sam-
ple. As further shown in Figure 3, the population of
diabetic patients with CKD generates 38% of all Medi-
care ESRD patients, and the population of nondiabetic
CKD patients generates 26% of all Medicare ESRD
patients; together, these 2 groups comprise two-thirds of
all Medicare patients who enter dialysis.
Figure 4 shows outcomes for 1996 to 1997 study pa-
tients during the 2-year follow-up, comparing these pa-
tients with the 1997 prevalent dialysis patients followed
for the same 2-year period. Patients with a diagnosis of
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Fig. 4. Outcomes for Medicare patients dur-
ing 2-year follow-up and comparison with
prevalent dialysis patients: risk of death vs.
end-stage renal disease. CKD, chronic kidney
disease; DM, diabetes mellitus; ESRD, end-
stage renal disease.
Fig. 5. Prevalence of cardiovascular disease in general Medicare pa-
tients in 1996-1997. ASHD, atherosclerotic heart disease; CHF, conges-
tive heart failure; CKD, chronic kidney disease; CVA/TIA, cerebrovas-
cular accident/transient ischemic attack; CVD, cardiovascular disease;
PVD, peripheral vascular disease.
CKD (with or without diabetes) were 5 to 10 times more
likely to die than to reach ESRD. The 30% to 32%
mortality at the end of 2-year follow-up is three-fourths
of the death rate for the comparison group of dialysis
patients, whose 2-year mortality was 40%. Patients with-
out a diagnosis of CKD (with or without diabetes) were
approximately 49 to 128 times more likely to die than
to reach ESRD. Their mortality rates at the end of fol-
low-up were 10% to 16%, about one-fourth to two-fifths
of the death rate of dialysis patients.
Figure 5 shows, by CKD status, the prevalence of
cardiovascular disease from 1996 to 1997 among patients
who survived and did not develop CKD or ESRD in
1998. Eighty percent of the approximately 28,000 pa-
tients with CKD in the 5% sample had at least 1 CVD
diagnosis code from 1996 to 1997. Non-CKD patients
had approximately half that rate. Rates for specific condi-
Fig. 6. Unadjusted incidence (per 100 patient-years at risk) of newly
diagnosed cardiovascular disease in general Medicare patients during
1998. ASHD, atherosclerotic heart disease; CHF, congestive heart fail-
ure; CKD, chronic kidney disease; CVA/TIA, cerebrovascular accident/
transient ischemic attack; CVD, cardiovascular disease; PVD, periph-
eral vascular disease.
tions in CKD patients were as follows: atherosclerotic
heart disease, 52%; congestive heart failure, 41%; cere-
bral vascular accidents and transient ischemic attacks,
27%; peripheral vascular disease, 36%; and other CVDs,
55%. In non-CKD patients, rates were approximately
half and often well less than half of the comparable rates
in CKD patients. As shown in Figure 6, among those
who did not have a diagnosis of CVD from 1996 to 1997,
the rate of acquiring these codes in the 1-year fixed
survival period (1998) was 24% for the CKD patients
and 15% for the non-CKD patients.
Figures 7 and 8 present life table estimates of the
probability of acquiring diagnosis codes for CVD and
congestive heart failure, respectively, during the 1-year
fixed survival period (1998). Codes for cardiovascular
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Fig. 7. Life table estimates for probability
of incident cardiovascular disease in general
Medicare patients during 1998. P 0.0001 for
all log-rank tests for differences among patient
groups. CKD, chronic kidney disease; CVD,
cardiovascular disease; ESRD, end-stage re-
nal disease; RR, relative risk.
Fig. 8. Life table estimates for probability of
incident congestive heart failure in general
Medicare patients during 1998. P 0.0001 for
all log-rank tests for differences among patient
groups. CHF, congestive heart failure; CKD,
chronic kidney disease; ESRD, end-stage re-
nal disease; RR, relative risk.
disease were acquired by 24% of those with CKD and
only 15% of those without CKD. The relative risk that
a new cardiovascular disease code would be recorded
was 1.61 [95% confidence interval (CI), 1.52 to 1.69]
times greater in the CKD population than in the non-
CKD population (Fig. 7). The code for congestive heart
failure was acquired by 11% of those with CKD and
only 4.5% of those without CKD; hence, there was a
2.23 (95% CI, 2.13 to 2.34) times greater likelihood that
a new code for congestive heart failure or related services
would be recorded in the CKD population (Fig. 8).
The rate at which diagnoses are reported differed for
patient populations that survived the 1998 follow-up pe-
riod with or without advancing to ESRD, or dying before
reaching ESRD. As shown in Figures 7 and 8, CVD in
general, and congestive heart failure, in particular, were
documented at a similar rate in those who advanced to
ESRD in the fourth year of study or died before reaching
ESRD. These rates were considerably higher than those
in patients who survived the follow-up period without
either event, those who had reported CVD and conges-
tive heart failure at one-third to two-thirds the rate of
those reaching ESRD, and those who died before reach-
ing ESRD.
Figure 9 shows hospitalization rates for CKD, non-
CKD, and dialysis patients aged 65 years and older and
followed through 1999, according to the presence or ab-
sence of diabetes. For dialysis patients, the all-cause hos-
pitalization rates were almost 5 times greater than those
for non-CKD patients. Chronic kidney disease patients
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Fig. 9. Hospitalization rates by diagnosis, patient population, and dia-
betic status. CKD, chronic kidney disease; CVD, cardiovascular disease.
Fig. 10. Cardiovascular hospitalization rates by diagnosis and patient
population. CHF, congestive heart failure; CKD, chronic kidney disease;
CVD, cardiovascular disease; IHD, ischemic heart disease.
had hospitalization rates that were 2.5 times greater than
those for non-CKD patients. In both diabetics and nondi-
abetics, CVD and infectious complications were highest
in dialysis patients, intermediate in CKD patients, and
lowest in non-CKD patients. Figure 10 gives the cause-
specific cardiovascular hospitalization rates for CKD,
non-CKD, and dialysis patients aged 65 years and older
and followed through 1999. Chronic kidney disease pa-
tients had intermediate hospitalization rates for conges-
tive heart failure, ischemic heart disease, and other CVD.
Dialysis patients had the highest rate of hospitalization
for other CVDs. Chronic kidney disease patients had a
disproportionately high rate of hospitalization for con-
gestive heart failure, being almost 5 times greater than
Fig. 11. Percentage of patients with incident end-stage renal disease
receiving diabetic care in the year before and after initiation of dialysis.
ESRD, end-stage renal disease; Hb, hemoglobin.
that of non-CKD patients and only one-third lower than
that of dialysis patients.
To reduce cardiovascular complications in diabetic
patients, the American Diabetes Association and the
American Heart Association have recommended the
performance of lipid studies and glycosylated hemoglo-
bin testing [17–19]. Figure 11 shows the percentage of
patients with incident ESRD who received these indica-
tors of preventive diabetic care in the year before and
after initiation of dialysis. Between the years 1995 and
1996, these indicators were documented in nearly 50%
of patients in the year before dialysis initiation. However,
this rate was lower after patients started dialysis. In 1997
through 1999, comparable percentages of patients re-
ceived lipid monitoring and glycosylated hemoglobin
testing before and after starting dialysis, despite the fact
that dialysis patients were seen on a regular basis (for
administration of their dialytic therapy).
DISCUSSION
Recent publications on the extent of CKD in the gen-
eral population have highlighted a major public health
concern: the ever-increasing number of individuals reach-
ing ESRD treatment [10, 11]. The Healthy People 2010
objectives to reduce the incident rates of ESRD and
the cardiovascular death rates of those who have CKD
suggest that payers and providers need to identify these
high-risk populations for active intervention. The Na-
tional Kidney Foundation’s CKD guidelines have pro-
vided a detailed set of recommendations on the care of
CKD patients [11], and subsequent guidelines have be-
gun to focus on the high burden of CVD associated with
the CKD population [20].
A large proportion of the CKD population is located,
as expected, within the diabetic population and/or the
Medicare population. On the basis of the CDC’s Behav-
ioral Risk Factor Surveillance System survey [14–16] and
our direct assessment of the extent of diabetes within
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the Medicare population, it appears the annual rate of
increase in the prevalence of diabetes is 4.2% to 4.4%
per year. The group of 3.7 million individuals (estimated
on the basis of the 5% Medicare sample) with a diagnosis
of diabetes contains within it a much smaller subgroup,
approximately one-tenth the size, of patients with diag-
noses of both diabetes and CKD. Within the ESRD
population, this subgroup has a percentage that is almost
30 times its percentage in the general Medicare popula-
tion. Within the ESRD population, nondiabetics with a
diagnosis of CKD have a percentage that is approxi-
mately 13 times their percentage in the general Medicare
population. The death rate during follow-up is striking.
In the general Medicare population, diabetics with a
diagnosis of CKD have a mortality rate of almost 32%
in the next 2 years, or three-fourths that of the dialysis
population. This mortality rate dramatizes the extraordi-
nary risk in this group of patients.
Although one could argue that CKD that has been
given a diagnosis code represents clinically apparent dis-
ease and not mild disease, it nevertheless identifies indi-
viduals who were well known to the providers who sub-
mitted claims for clinical care services. The high death
rate, which has not been identified previously, partly
explains the difference between the high prevalence of
CKD and the low incident rate of ESRD (only 100,000
patients per year starting ESRD treatment). Our findings
suggest that the approximately 6 million Medicare en-
rollees with CKD and an eGFR of 60 mL/min are 5
to 10 times more likely to die than they are to develop
ESRD. These deaths appear to be attributable to CVD.
Because almost 80% of Medicare enrollees who have
a CKD diagnosis code also have a diagnosis code for
CVD (twice the rate of the non-CKD population), we
investigated the rate of acquisition of these diagnoses
and services in individuals who did not have a diagnosis
of CVD, finding that CKD patients are 60% more likely
than non-CKD patients to acquire CVD diagnosis codes
and services over a 1-year period. Even more striking is
the rate of diagnosis and services for congestive heart
failure, a common complication of advancing CKD and
ESRD; in CKD patients, this rate is 2.23 times greater
than that in non-CKD patients. Equally important is the
observation that the rates of acquisition of CVD and
congestive heart failure diagnosis codes appear similar
between those who die in the fourth year and those who
advance to ESRD or CKD. These findings suggest that
CKD patients who are advancing toward ESRD carry
the heaviest burden of CVD and that this frequently
leads to death before ESRD is reached. Ironically, it is
the fortunate patients who survive to ESRD. Our find-
ings allow insight not only on the high mortality rate of
the CKD patients (versus non-CKD patients), but also
on the high rates of CVD and death in the elderly ESRD
population. As survivors of CKD, ESRD patients, in fact,
represent a biased sample; outcome data were previously
unavailable on non-survivors.
Limitations to our study should be considered. First,
we identified CKD patients using a coding methodology
that would capture only patients with more advanced
disease. The USRDS has attempted to estimate the level
of eGFR present in the Medicare CKD population by
comparing the proportions in the National Health and
Nutrition Examination Survey (NHANES) III popula-
tion. On the basis of regressions to the NHANES III
1988-1994 period, the Medicare CKD population ap-
pears to have an eGFR of 34 5 mL/min, or late stage III
CKD. Because we identified only 1.2 million Medicare
enrollees with a diagnosis code for CKD, and the
NHANES III estimate of the number of patients with
an eGFR of 60 mL/min was 5.9 million, it appears we
found only one-sixth of the cases. Despite this limitation,
it is clear that our Medicare subjects had clinically recog-
nized disease, and their conditions would not have been
considered a reduced eGFR secondary to aging. The
methodology we used did identify a very large CKD
group that contributes to the Medicare ESRD incident
population (64%). The methods we used to identify the
causes of hospitalization may overestimate the burden,
since CVD hospitalizations have higher reimbursement
levels than do hospitalizations for other disease states.
That these CKD patients have congestive heart failure
is in little doubt, since it is a major complication of
advancing kidney failure and a major indication for initi-
ation of dialysis. The disproportionate hospitalization
rate for patients with congestive heart failure is consis-
tent with the clinical complication of CKD; from this
perspective, the qualitative and quantitative findings are
consistent. The preventive care measures investigated
do not indicate the level of control achieved in regard
to lipid levels or glycemia because billing records of
payment for the test do not include test results. What is
surprising is the underutilization of these recommended
measures, particularly in high-risk patients with known
CKD. The direct investigation of achieved control of
lipid disorders and hyperglycemia would have been pref-
erable but was not possible in this large national study.
More detailed data collection will be needed to address
this area.
CONCLUSION
Overall, the morbidity of the Medicare CKD popula-
tion is significant. Cardiovascular admissions occur at
twice the rate of that in the non-CKD population. Infec-
tious complications are also 2 to 3 times greater than in
the non-CKD population. In terms of CVD, heart failure
is almost 5 times greater in the CKD population than in
the non-CKD population and is two-thirds the rate in
the dialysis population. Given this heavy burden of CVD,
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cardiovascular hospitalizations, and earlier death, pre-
ventive health care measures and more proactive care
appear to be needed. Primary care providers, who dis-
pense most of the care to this high-risk population, face
considerable challenges given the limited time they have
to see patients in their practices. Alternative care systems
may be needed to address this unique high-risk popula-
tion. Hopefully, with the increased attention that this
and other studies are giving to CKD, we can achieve the
Healthy People 2010 objectives of reducing the cardio-
vascular death rate in patients with kidney disease and
slowing the rate at which CKD patients advance to
ESRD.
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